索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]杨洁,张凤如,沈卫峰.心力衰竭药物治疗进展[J].国际心血管病杂志,2015,06:380-383.
点击复制

心力衰竭药物治疗进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2015年06期
页码:
380-383
栏目:
综述
出版日期:
2015-11-25

文章信息/Info

Title:
-
作者:
杨洁; 张凤如; 沈卫峰
200025,上海交通大学医学院附属瑞金医院心内科
Author(s):
-
关键词:
心力衰竭; 心功能; 治疗
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2015.06.004
文献标识码:
-
摘要:
尽管心力衰竭的管理和治疗策略取得了较大进展,但其发病率及死亡率仍较高。其中急性心力衰竭(acuteheartfailure,AHF)更是临床上的危急重症,若不及时抢救,死亡率极高。近年来,有关AHF的药物治疗研究逐渐增多,在改善呼吸困难等症状及挽救终末器官功能上均有一定的疗效。
Abstract:
-

参考文献/References

[1] Jeyabalan A, Shroff SG, Novak J, et al.The vascular actions of relaxin[J].Adv Exp Med Biol,2007,612:65-87.
[2] Conrad KP. Maternal vasodilation in pregnancy: the emerging role of relaxin [J]. Am J Physiol Regul Integr Comp Physiol,2011,301(2):267-275.
[3] Dschietzig T, Teichman S, Unemori E, et al. Intravenous recombinant humanrelaxin in compensated heart failure:asafety,tolerability and pharmacodynamic trial[J].J Card Fail,2009,15(3):182-190.
[4] Teerlink JR, Metra M, Felker GM, et al. Relaxin for thetreatment of patients with acute heart failure(Pre-RELAX- AHF): a multicentre,randomized, placebo-controlled,parallel-group,dose-finding phase Ⅱb study[J].Lancet,2009, 373(9673):1429-1439.
[5] Svendsen AM, Zalesko A, Konig J, et al. Negativecooperativity in H2 relaxin binding to a dimericrelaxin family peptidereceptor1[J].Mol Cell Endocrinol,2008,296(1-2):10-17.
[6] Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure(RELAX-AHF): a randomised, placebo-controlled trial[J].Lancet, 2013,381(9860):29-39.
[7] Metra M, Cotter G, Davison BA, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure(RELAX-AHF)development program: correlation with outcomes[J]. J Am Coll Cardiol,2013, 61(2):196-206.
[8] Cotter G, Milo O, Davison BA. Increased mortality after an acute heart failure episode: new pathophysiological insights from the RELAX-AHF study and beyond[J]. Curr Heart Fail Rep,2014,11(1):19-30.
[9] 王 君,郑兴.心力衰竭新药的临床研究[J].国际心血管病杂志,2014,41(2):72-74.
[10] O'Connor CM, Starling RC, Hernandez AF,et al. Effect of nesiritide in patients with acute decompensated heart failure[J]. N Engl J Med,2011,365(1):32-43.
[11] Lüss H, Mitrovic V, Seferovic PM,et al.Renal effects of ularitide in patients with decompensated heart failure[J]. Am Heart J, 2008,155(6):1012.e1-e8.
[12] Nomura F, Kurobe N, Mori Y, et al. Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart Failure Study[J]. Circ J,2008,72(11):1777-1786.
[13] Hattori H, Minami Y, Mizuno M, et al. Differences in hemodynamic responses between intravenous carperitide and nicorandil in patients with acute heart failure syndromes[J]. Heart Vessels,2013,28(3):345-351.
[14] Erdmann E, Semigran MJ, Nieminen MS, et al. Cinaciguat, a soluble guanylatecyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure[J]. Eur Heart J, 2013,34(1):57-67.
[15] Gheorghiade M, Greene SJ, Filippatos G, et al. Cinaciguat, a soluble guanylatecyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes[J]. Eur J Heart Fail, 2012,14(9):1056-1066.
[16] Delaney A, Bradford C, McCaffrey J, et al.Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials[J]. Int J Cardiol,2010,138(3):281-289.
[17] 边长勇,尹宗宪,李 涛,等.左西孟旦治疗射血分数正常充血性心力衰竭患者的短期疗效[J].国际心血管病杂志,2014,41(3):192-194.
[18] Malik FI, Hartman JJ, Elias KA, et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure[J]. Science,2011,331(6023):1439-1443.
[19] Cleland JG, Teerlink JR, Senior R, et al. The effects of the cardiac myosin activator, omecamtivmecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial[J]. Lancet, 2011,378(9792):676-683.
[20] Teerlink JR, Clarke CP,SaikaliKG,et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtivmecarbil: a first-in-man study[J]. Lancet,2011,378(9792):667-675.
[21] Valentova M, von Haehling S.An overview of recent developments in the treatment of heart failure: update from the ESC Congress 2013[J]. Expert OpinInvestig Drugs,2014,23(4):573-578.
[22] 张凤如.急性心力衰竭内科治疗现状与展望[J].国际心血管病杂志,2011,38(6):339-341.
[23] Gheorghiade M, Blair JE, Filippatos GS,et al. Hemodynamic,echocardiographic,andneurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure[J].J Am Coll Cardiol, 2008, 51(23):2276-2285.
[24] Shah SJ, Blair JE, Filippatos GS et al.Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure(HORIZON-HF)trial[J]. Am Heart J,2009,157(6):1035-1041.
[25] Von Lueder TG, Sangaralingham SJ, Wang BH, et al. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure[J].Circ Heart Fail,2013,6(3):594-605.
[26] Pham AQ, Patel Y,GallagherB,et al.LCZ696(angiotensin-neprilysin inhibition): the new kid on the heart failure block? [J].J Pharm Pract,2015,28(2):137-145.
[27] Hedge LG, Yu C, Renner T, et al. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat[J]. J Cardiovasc Pharmacol,2011,57(4):495-504.
[28] Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomized controlled trial[J]. Lancet,2012,380(9851):1387-1395.
[29] McMurray JJ, Packer M, DesaiAS,et al. Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial(PARADIGM-HF)[J].Eur J Heart Fail,2014,16(7):817-825.
[30] Filippatos G, Farmakis D, Parissis J, et al. Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice[J]. BMC Med,2015,13:35.
[31] Gheorghiade M. BohmM,GreeneSJ,et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalizedfor heart failure: the ASTRONAUT randomized trial[J]. JAMA,2013,309(11):1125-1135.
[32] Maggioni AP, Greene SJ, Fonarow GC, et al. Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial[J]. Eur Heart J,2013,34(40):3117-3127.
[33] Boerrigter G, Soergel DG, Violin JD,et al.TRV120027, a novel β-arrestin biased ligand at the angiotensin Ⅱ type Ⅰ receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure[J]. Circ Heart Fail,2012,5(5):627-634.

备注/Memo

备注/Memo:
通信作者:沈卫峰,Email:rjshenweifeng@126.com
更新日期/Last Update: 2015-12-20